Medication info

Starova Tablet 20mg (Rosuvastatin Calcium)

Prescription medicationTabletApproval withdrawn
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
BC World Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets (15 tablets/PTP (AluAlu) × 2)
Approval status
Approval withdrawn

MFDS item code 201907232 · Approved 2019.10.15

This product's status changed to Approval withdrawn on 2024.11.13. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving this medicine, both before and during treatment, should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Children's dosage
Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
BC World Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • dysbetalipoproteinemia
  • primary dysbetalipoproteinemia
  • elevated high sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is primarily used as an adjunct for patients with hypercholesterolemia and mixed dyslipidemia when diet or exercise is not sufficient. It is particularly beneficial for patients with primary hypercholesterolemia, familial hypercholesterolemia, and dysbetalipoproteinemia. It helps lower total cholesterol and LDL cholesterol levels to slow the progression of atherosclerosis. It is also used in pediatric patients aged 10 to 17 years with familial hypercholesterolemia. For men over 50 years and women over 60 years with high sensitivity C-reactive protein levels and cardiovascular risk factors, it helps reduce the risk of stroke, myocardial infarction, and vascular revascularization procedures. This medication is used to improve cardiovascular health and reduce the risk of cardiovascular diseases.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving this medicine, both before and during treatment, should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Children's dosage

Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patients. Firstly, individuals allergic to this medication should avoid it. Patients with severely impaired liver function or active liver disease should not use this medication. It should also not be administered to patients with muscle disorders or those experiencing muscle problems. Additionally, patients taking the immunosuppressant cyclosporine should not use this medication. Patients with very poor kidney function, pregnant or nursing women, and women of childbearing age who are uncertain about pregnancy should also avoid this medication. High doses (40 mg) are contraindicated, especially in patients at high risk for muscle problems. Patients with genetic metabolic disorders such as lactose intolerance should not take this medication. This medication should be used with caution in patients who consume alcohol excessively or have a history of liver disease, and liver function tests should be performed regularly before and during administration. Patients with conditions such as hypothyroidism or nephrotic syndrome should first have those conditions treated before using this medication. If symptoms such as muscle pain or weakness occur, the physician should be informed immediately, and if necessary, the medication should be discontinued. This medication can rarely cause severe adverse reactions such as serious skin reactions, liver damage, or muscle damage, so if such symptoms occur, treatment should be stopped immediately and medical consultation sought. Furthermore, this medication may interact with other drugs, so if taking any other medications, patients should inform their doctor or pharmacist. In particular, the risk of muscle damage may increase when used in conjunction with certain antivirals, immunosuppressants, antibiotics, or fibrate drugs. Pregnant or nursing women should not use this medication, and women who are capable of becoming pregnant should use appropriate contraception. In the event of overdose, there is no specific antidote, so treatment should be symptomatic, and liver function and muscle enzyme levels should be monitored. Dizziness may occur when driving or operating machinery, so caution is advised. It is important to have regular check-ups as advised by a physician during the course of this medication, and to consult a healthcare provider immediately if abnormal symptoms arise.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, difficulty breathing, diarrhea, ophthalmoplegia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, drug-induced eczematous rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, numbness, dysesthesia, chest discomfort, anorexia, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly closed container to protect it from air and moisture. It is recommended to keep the storage temperature between 1 to 30 degrees Celsius at room temperature to maintain the drug's efficacy and safety over time.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets (15 tablets/PTP (AluAlu) × 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.